Skip to main content
Clinical Trials/NCT05212727
NCT05212727
Terminated
Not Applicable

Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders

Innodem Neurosciences1 site in 1 country300 target enrollmentApril 15, 2022
InterventionsEye-tracking

Overview

Phase
Not Applicable
Intervention
Eye-tracking
Conditions
Neurological Disorders
Sponsor
Innodem Neurosciences
Enrollment
300
Locations
1
Primary Endpoint
Symbol Digit Modalities Test (SDMT) score, one time, at the day of enrolment.
Status
Terminated
Last Updated
26 days ago

Overview

Brief Summary

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.

This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.

Registry
clinicaltrials.gov
Start Date
April 15, 2022
End Date
May 3, 2024
Last Updated
26 days ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years old and above
  • A score of ≥ 26 on the Montreal Cognitive Assessment (MoCA)
  • Able to provide informed consent
  • Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc are permitted).

Exclusion Criteria

  • Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
  • Evidence or history of significant neurological disorder (e.g. MS, PD, ALS, Dementia)
  • Use of prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics, and anticonvulsants.
  • Diagnosed with an active substance use disorder.
  • History of stroke.
  • Recent traumatic brain injury (within the last 6 months).

Arms & Interventions

Healthy Control

Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.

Intervention: Eye-tracking

Outcomes

Primary Outcomes

Symbol Digit Modalities Test (SDMT) score, one time, at the day of enrolment.

Time Frame: Baseline

The SDMT is used to assess divided attention, visual scanning, tracking and motor speed. Using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. Scoring involves summing the number of correct substitutions within the 90 second interval.

Secondary Outcomes

  • Multiple sclerosis functional composite (MSFC) score, one time, at the day of enrolment.(Baseline)
  • The Mini-Mental State Exam (MMSE) score, one time, at the day of enrolment.(Baseline)
  • The Hopkins Verbal Learning Test-Revised (HVLT-R) score, one time, at the day of enrolment.(Baseline)
  • The Controlled Oral Word Association Test (COWAT) score, one time, at the day of enrolment.(Baseline)
  • Brief International Cognitive Assessment for MS (BICAMS) score, one time, at the day of enrolment.(Baseline)
  • The Beck Anxiety Inventory (BAI), one time at the day of enrolment.(Baseline)
  • The Montreal Cognitive Assessment (MoCA) score, one time, at the day of enrolment.(Baseline)
  • The Trail Making Test (TMT) Parts A & B score, one time, at the day of enrolment.(Baserline)
  • The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), one time, at the day of enrolment.(Baseline)

Study Sites (1)

Loading locations...

Similar Trials